ESTRO37_ProgrammeBook

10:40 > Quantitative assessment of CAIX expression with SPECT imaging in head and neck cancer xenografts F. Huizing (The Netherlands), B.A.W. Hoeben, G. Franssen, O. Boerman, S. Heskamp, J. Bussink 10:50 > Technical and biological validation of hypoxia PET imaging using [18F] fluroazomycin (FAZA) in NSCLC

SUNDAY 22 APRIL 2018

OC-0266

A. Salem (United Kingdom), D. Gorman, H. Mistry, L. Joseph, R. Shah, H. Valentine, A. Jackson, C.M.L. West, C. Faivre-Finn, J. O’Connor, M.C. Asselin

OC-0267

11:00 > FAZA PET hypoxia as a marker of loco-regional recurrence in HNSCC? Results from the DAHANCA 24 trial M. Saksø (Denmark), L. Mortensen, H. Primdahl, J. Johansen, J. Kallehauge, C. Hansen, J. Overgaard

OC-0268

11:10 > Comparison of tumour hypoxia measured by FMISO-PET and gene signatures for patients with HNSCC

S. Löck (Germany), A. Linge, A. Seidlitz, A. Bandurska-Luque, M. Großer, G. Baretton, K. Zöphel, D. Zips, E. Troost, M. Krause, M. Baumann

OC-0269

11:20 > Imaging tumor hypoxia in prostate cancer patients by integration of multiparametric DW-MR images T. Hompland (Norway), K. Hole, H. Ragnum, L. Vlatkovic, T. Seierstad, H. Lyng

OC-0270

PROFFERED PAPERS CL 5: Head and neck 10:30 - 11:45  | ROOM AUDITORIUM

Chair: J. Giralt (Spain) Chair: P. Bonomo (Italy)

10:30 > 5-Y update of the randomized phase III trial DAHANCA19: Primary (Chemo) RT +/- zalutumumab in HNSCC

J.G. Eriksen (Denmark), C. Maare, J. Johansen, H. Primdahl, J. Evensen, C.A. Kristensen, L.J. Andersen, J. Overgaard

OC-0271

10:40 > Twice daily reirradiation with cetuximab vs once daily chemoRT after surgery in head and neck cancer Y. Tao (France), L. Faivre, A. Laprie, P. Boisselier, C. Ferron, G. Jung, S. Racadot, B. Gery, C. Even, I. Breuskin, J. Bourhis, F. Janot

OC-0272

SCIENTIFIC PROGRAMME | Programme and Exhibition Guide

112